米国のエソテリック検査（特殊検査）市場：規模・予測、地域シェア、動向、成長機会分析 - タイプ別、技術別、エンドユーザー別

米国のエソテリック検査市場は、2022年の103億8,200万米ドルから2030年には312億7,400万米ドルに成長すると予測され、2022年～2030年のCAGRは14.8%と推定されます。当レポートでは、市場の動向と市場成長を促進する要因について取り上げています。市場成長の要因は、慢性疾患の有病率の上昇と病状の早期発見に対する意識の高まりであり、これが米国の難分解性検査市場規模と成長を牽引しています。さらに、遺伝子検査の進歩や規制当局による希少疾患関連の取り組みが、予測期間中に市場の重要な動向として浮上する可能性が高いです。しかし、熟練した人材の不足と処置の高コストが、予測期間2022年～2030年の市場成長の妨げとなります。

病状の早期発見に対する意識の高まりが予測期間の市場を牽引

疾患の早期診断は、医療従事者や患者が、ケア、サポートの必要性、経済的・法的問題など、さまざまな重要な医療上の決定を下すのに役立ちます。特定の病状に関連する認知症状に気づいてから正確かつ早期の診断を得ることで、症状が悪化する前に回復させることができ、その後、患者に対して効果的かつ早期の治療を行うことができます。また、ヘルスケア専門家にとっても、より良い意思決定のための十分な時間を確保することができます。臨床検査は、神経疾患、遺伝病、がん、内分泌疾患など、専門分野に関連する疾患の診断のために広く行われています。糖尿病、心血管疾患、脂質異常症、がん、遺伝性疾患の診断には、エソテリック検査や遺伝子検査が行われています。

さまざまな政府規制機関も、早期診断の実践を促進するためのイニシアチブをとり、キャンペーンを実施しています。全米希少疾患機構は、教育、調査、アドボカシー、患者サービスなど数多くの支援プログラムを通じて、希少疾患の特定、診断、治療を目指しています。ニューヨーク州希少疾患ワークグループは、ニューヨーク州で可決された法律（公衆衛生法第27条のL）に対応して設立されたもので、希少疾患に対する認識を高めるためのベストプラクティスを特定することを目的としています。このような取り組みを通じて、希少疾患の可能性がある人々を専門医に紹介し、経済的課題を含む治療への障壁に対処することができます。複雑な遺伝的・非遺伝的希少疾患の利用可能な診断オプションに関する知識を構築するこのようなイニシアチブは、米国の難分解性検査市場の成長に有利です。

レポート区分と調査範囲

米国エソテリック検査市場は、タイプ、技術、エンドユーザーに基づいてセグメント化されます。タイプ別では、市場は感染症検査、内分泌学検査、腫瘍学検査、毒物学検査、免疫学検査、神経学検査、その他に区分されます。技術別では、米国の難分解性検査市場は、化学発光免疫測定法、酵素結合免疫吸着測定法、質量分析法、リアルタイムPCR法、DNAシークエンシング法、フローサイトメトリー法、その他に分けられます。エンドユーザーの観点からは、市場は病院と検査室、独立系検査室と基準検査室に分類されます。

米国のエソテリック検査市場は、タイプ別に感染症検査、内分泌学検査、腫瘍学検査、毒物学検査、免疫学検査、神経学検査、その他に区分されます。2022年には腫瘍学検査分野が最大の市場シェアを占めています。感染症検査分野は、2022年から2030年にかけて最も高いCAGRを記録すると予測されています。

技術別に見ると、米国の難分解性検査市場は、化学発光免疫測定法、酵素結合免疫吸着測定法、質量分析法、リアルタイムPCR法、DNAシークエンシング法、フローサイトメトリー法、その他に区分されます。化学発光免疫測定法は2022年に最大の市場シェアを占めました。酵素結合免疫吸着測定法セグメントは、2022年～2030年に18.7%の最高CAGRを記録すると予測されています。

エンドユーザーに基づき、米国のエソテリック検査市場は病院と検査室、独立系検査室と基準検査室に区分されます。2022年の市場シェアは、病院・検査室セグメントが大きいです。さらに、2022年～2030年のCAGRは15.2％と高くなると予想されています。

エソテリック検査は一般的に、通常の検査では結論の出ない希少でユニークな物質の分析のために実施されます。これらの検査を実施するためには、臨床検査室は関連する専門分野の専門知識を必要とします。そのため、大規模な臨床検査室はこれらの複雑な検査をレファレンス検査室や難分解性検査室に委託しています。米国で難解な検査を行っている検査施設には、Quest Diagnostics Incorporated、Mayo Medical Laboratories、ARUP Laboratories、Myriad Genetics、Genomic Health、Foundation Medicine、Laboratory Corporation of Americaなどがあります。このような特殊な検査を実施できる検査施設の数は、この地域で増加しています。

2022年1月に発表された内分泌学会の論文によると、性腺機能低下症は男性集団によく見られる疾患で、高齢男性、肥満男性、2型糖尿病男性で有病率が高いです。45歳以上の男性の35％、2型糖尿病または肥満の男性の30～50％が性腺機能低下症であると推定されています。さらに、米国国勢調査局の推計によれば、65歳以上の男性における性腺機能低下症の罹患率は、2000年の～3500万人から2020年には～5500万人に増加します。さらに、2050年には8,700万人に増加すると推定されています。この疾患の有病率が急上昇している背景には、米国における老人人口の増加があります。

難解な検査に対する需要の急増も、肝硬変の症例が増加していることに起因しています。Statistaによると、米国では2020年に51,642人の成人が肝疾患で死亡しています。慢性肝疾患/肝硬変は、2020年の米国における死亡原因の第12位であり、アルコール性肝硬変の増加もこの疾患の主な危険因子です。

さらに、コラボレーションやパートナーシップも米国における難分解性検査の市場成長を促進すると予想されています。例えば、2021年10月の米国国立衛生研究所（NIH）のプレスリリースによると、NIH、米国食品医薬品局、製薬会社10社、非営利団体5団体が、希少疾患に苦しむ3,000万人の米国人のための遺伝子治療の開発を加速させるために参加しています。希少疾患は7000近くあるが、現在FDAが遺伝子治療を承認している遺伝性疾患は2つしかないです。最近発足したBespoke Gene Therapy Consortium（BGTC）は、NIHのAccelerating Medicines Partnership（AMP）プログラムの一部門であり、NIHの財団がプロジェクトを主導しています。

このように、性腺機能低下症、肝硬変、その他のこのような疾患の症例が急増していることが、米国の難分解性検査市場の成長を牽引しています。

米国の難分解性検査市場の企業は、様々な有機的・無機的戦略を採用しています。有機的戦略には主に製品の発売と製品承認が含まれます。さらに、市場で示される無機的な成長戦略は、買収、提携、パートナーシップです。これらの成長戦略により、市場企業は事業を拡大し、地理的プレゼンスを高めることができ、それによって市場全体の成長に貢献します。さらに、買収と提携戦略は、市場企業が顧客基盤を強化し、製品ポートフォリオを拡大するのに役立ちます。米国の難分解性検査市場における主要企業の重要な発展のいくつかを以下に示します。

The American Heart Association, The American Thyroid Association, The United States Food and Drug Administration（FDA）, MyBioSource.com., The Endocrine Society National Institutes of Health（NIH）などは、米国の難分解性検査市場に関するレポートを作成する際に参照した主な一次情報源および二次情報源です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 米国のエソテリック検査市場情勢

• PEST分析
  • 米国のPEST分析

第5章 米国のエソテリック検査市場：主要産業力学

• 主な市場促進要因
  • 慢性疾患の有病率の上昇
  • 病状の早期発見に対する意識の高まり
• 主な市場抑制要因
  • 熟練者の不足と検査費用の高騰
• 主な市場機会
  • 市場企業の戦略的取り組み
• 今後の動向
  • 遺伝子検査技術の発展と希少疾患に対する政府の取り組みの増加
• 影響分析

第6章 米国のエソテリック検査市場：収益と2030年までの予測

• 米国のエソテリック検査市場の収益（2022年～2030年）

第7章 米国のエソテリック検査市場：収益と2030年までの予測 - 技術別

• 米国のエソテリック検査市場：2022年および2030年の収益シェア - 技術別
• 化学発光免疫測定法
• 酵素結合免疫吸着測定法
• 質量分析
• リアルタイムPCR
• フローサイトメトリー
• DNAシーケンス
• その他

第8章 米国のエソテリック検査市場：収益と2030年までの予測 - タイプ別

• 米国のエソテリック検査市場：2022年および2030年の収益シェア - タイプ別
• 感染症検査
• 内分泌学検査
• 腫瘍学検査
• 毒物学検査
• 免疫学検査
• 神経学検査
• その他

第9章 米国のエソテリック検査市場：収益と2030年までの予測 - エンドユーザー別

• 米国のエソテリック検査市場：2022年および2030年の収益シェア - エンドユーザー別
• 病院・研究所
• 独立系・リファレンスラボ

第10章 米国のエソテリック検査市場：業界情勢

• 有機的展開
• 無機的展開

第11章 企業プロファイル

• Georgia Esoteric & Molecular Laboratory LLC
• Laboratory Corp of America Holdings
• Quest Diagnostics Inc
• National Medical Services Inc
• OPKO Health Inc
• ARUP Laboratories Inc
• bioMONTR Labs
• Athena Esoterix LLC
• Stanford Hospital & Clinics
• Foundation Medicine Inc

第12章 付録

List Of Tables

• Table 1. US Esoteric Testing Market Segmentation
• Table 2. US Esoteric Testing Market, by Type - Revenue and Forecast to 2030 (US$ Million)
• Table 3. US Esoteric Testing Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
• Table 4. US Esoteric Testing Market, by End User - Revenue and Forecast to 2030 (US$ Million)
• Table 5. Organic Developments in the US Esoteric Testing Market
• Table 6. Inorganic Developments in the US Esoteric Testing Market
• Table 7. Glossary of Terms, US Esoteric Testing Market

List Of Figures

• Figure 1. US Esoteric Testing Market Segmentation
• Figure 2. US - PEST Analysis
• Figure 3. US Esoteric Testing Market: Key Industry Dynamics
• Figure 4. US Esoteric Testing Market: Impact Analysis of Drivers and Restraints
• Figure 5. US Esoteric Testing Market Revenue (US$ Mn), 2020 - 2030
• Figure 6. US Esoteric Testing Market Revenue Share, by Technology 2022 & 2030 (%)
• Figure 7. Chemiluminescence Immunoassay: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 8. Enzyme-Linked Immunosorbent Assay: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 9. Mass Spectrometry: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 10. Real-Time PCR: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 11. Flow Cytometry: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 12. DNA Sequencing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Others: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 14. US Esoteric Testing Market Revenue Share, by Type 2022 & 2030 (%)
• Figure 15. Infectious Disease Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 16. Endocrinology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 17. Oncology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. Toxicology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. Immunology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. Neurology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 21. Others: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 22. US Esoteric Testing Market Revenue Share, by End User 2022 & 2030 (%)
• Figure 23. Hospitals & Laboratories: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 24. Independent & Reference Laboratories: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)

The US Esoteric Testing market is expected to grow from US$ 10.382 billion in 2022 to US$ 31.274 billion by 2030; it is estimated to grow at a CAGR of 14.8% from 2022 to 2030. The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the rising prevalence of chronic diseases and growing awareness of early detection of medical conditions, which are driving the US's esoteric testing market size and growth. Additionally, advancements in genetic testing and rare disease-related initiatives by regulatory authorities are likely to emerge as a significant trend in the market during the forecast period. However, the lack of skilled personnel and the high cost of procedure hinder market growth during the forecast period 2022-2030.

Growing Awareness of Early Detection of Medical Conditions drives the market in the forecast period.

The early diagnosis of diseases helps medical professionals and patients to make various important medical decisions in terms of care, support needs, and financial and legal matters. Obtaining accurate and early diagnosis after noticing cognitive symptoms related to a specific medical condition results in the reversal of symptoms before they are aggravated, followed by an effective and early treatment of patients. It also provides healthcare professionals sufficient time for better decision-making. Laboratory examination procedures are widely performed for the diagnosis of diseases associated with medical specialties, such as neurological disorders, genetic diseases, cancer, and endocrinological disorders. Esoteric testing and genetic testing are performed for the diagnosis of diabetes, cardiovascular disease, lipid disorders, cancer, and genetic diseases.

Various government regulatory bodies are also taking initiatives and conducting campaigns to promote early diagnosis practices. The National Organization for Rare Disorders aims to identify, diagnose, and treat rare disorders through numerous supportive programs, including education, research, advocacy, and patient services. The New York State Rare Disease Workgroup, created in response to legislation passed in New York State (Article 27-L of the Public Health Law), aims to identify best practices that could enhance the awareness of rare diseases. Through such initiatives, people potentially having rare diseases can be referred to specialists, and barriers to their treatments, including financial challenges, can be addressed. Such initiatives to build knowledge regarding available diagnosis options for complex genetic and non-genetic rare disorders favor the growth of the US esoteric testing market.

Report Segmentation and Scope -

The "US Esoteric Testing market" is segmented on the basis of type, technology, and end user. Based on type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. In terms of technology, the US esoteric testing market is divided into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. In terms of end users, the market is categorized into hospitals and laboratories and independent and reference laboratories.

The US esoteric testing market, by type, is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. The oncology testing segment held the largest market share in 2022. The infectious disease testing segment is anticipated to register the highest CAGR from 2022 to 2030.

Based on technology, the US esoteric testing market is segmented into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. The chemiluminescence immunoassay segment held the largest market share in 2022. The enzyme-linked immunosorbent assay segment is anticipated to register the highest CAGR of 18.7% during 2022-2030.

Based on end users, the US esoteric testing market is segmented into hospitals and laboratories, as well as independent and reference laboratories. The hospitals and laboratories segment held a larger share of the market in 2022. It is further expected to register a higher CAGR of 15.2% during 2022-2030.

Esoteric tests are generally performed for the analysis of rare and unique substances that are not concluded in regular tests. To perform these tests, clinical laboratories require expertise in relevant specialties. Therefore, large commercial laboratories outsource these complex tests to reference and esoteric testing laboratories. A few of the labs performing esoteric testing in the US include Quest Diagnostics Incorporated, Mayo Medical Laboratories, ARUP Laboratories, Myriad Genetics, Genomic Health, Foundation Medicine, and Laboratory Corporation of America. The number of laboratories that can perform these specialized tests is increasing in the region.

As per an article by the Endocrine Society, published in January 2022, hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. 35% of men older than 45 years of age and 30-50% of men with type 2 diabetes or obesity are estimated to have hypogonadism. Moreover, as per the US Census Bureau's estimation, the incidences of hypogonadism in men aged 65 years and more grew from ~35 million in 2000 to ~55 million by 2020. Further, it is estimated to rise to ~87 million by 2050. The surging prevalence of this condition is due to the rise in the geriatric population in the US.

An upsurge in the demand for esoteric testing is also attributed to the rising cases of hepatic cirrhosis. As per Statista, 51,642 adults in the US died from liver disease in 2020. Chronic liver disease/cirrhosis was the 12th leading cause of mortality in the US in 2020; an increase in the incidences of alcoholic cirrhosis is a major risk factor for this disease.

Furthermore, collaborations and partnerships are also expected to propel the market growth of esoteric testing in the US. For instance, as per The National Institutes of Health (NIH) press release of October 2021, NIH, the US Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations have joined to fasten the development of gene therapies for the 30 million Americans who suffer from rare diseases. Whereas there are nearly 7,000 rare diseases, currently, only 2 heritable diseases have FDA-approved gene therapies. The recently launched Bespoke Gene Therapy Consortium (BGTC), a section of the NIH Accelerating Medicines Partnership (AMP) program and project-lead by the Foundation of NIH, aims to enhance and streamline the development process of gene therapy to support the unmet medical needs of people with rare diseases.

Thus, the burgeoning cases of hypogonadism, hepatic cirrhosis, and other such disease is driving the growth of the esoteric testing market in the US.

Companies in the US's esoteric testing market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the US's esoteric testing market are listed below.

The American Heart Association, The American Thyroid Association, The United States Food and Drug Administration (FDA), MyBioSource.com., The Endocrine Society National Institutes of Health (NIH) are a few of the major primary and secondary sources referred to while preparing the report on the US Esoteric Testing market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US esoteric testing market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the US esoteric testing market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. US Esoteric Testing Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
  • 4.2.1 US PEST Analysis

5. US Esoteric Testing Market - Key Industry Dynamics

• 5.1 Market Drivers
  • 5.1.1 Rising Prevalence of Chronic Diseases
  • 5.1.2 Growing Awareness of Early Detection of Medical Conditions
• 5.2 Key Market Restraints
  • 5.2.1 Lack of Skilled Personnel and High Cost of Procedure
• 5.3 Key Market Opportunities
  • 5.3.1 Strategic Initiatives by Market Players
• 5.4 Future Trends
  • 5.4.1 Development in Genetic Testing Technologies and Increased Government Initiatives for Rare Diseases
• 5.5 Impact Analysis

6. US Esoteric Testing Market - Revenue and Forecast to 2030

• 6.1 US Esoteric Testing Market Revenue (US$ Mn), 2022 - 2030
  • 6.1.1 US Esoteric Testing Market, by Type, 2020-2030 (US$ Million)
  • 6.1.2 US Esoteric Testing Market, by Technology, 2020-2030 (US$ Million)
  • 6.1.3 US Esoteric Testing Market, by End User, 2020-2030 (US$ Million)

7. US Esoteric Testing Market - Revenue and Forecast to 2030 - by Technology

• 7.1 Overview
• 7.2 US Esoteric Testing Market Revenue Share, by Technology 2022 & 2030 (%)
• 7.3 Chemiluminescence Immunoassay
  • 7.3.1 Overview
  • 7.3.2 Chemiluminescence Immunoassay: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Enzyme-Linked Immunosorbent Assay
  • 7.4.1 Overview
  • 7.4.2 Enzyme-Linked Immunosorbent Assay: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Mass Spectrometry
  • 7.5.1 Overview
  • 7.5.2 Mass Spectrometry: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Real-Time PCR
  • 7.6.1 Overview
  • 7.6.2 Real-Time PCR: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.7 Flow Cytometry
  • 7.7.1 Overview
  • 7.7.2 Flow Cytometry: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.8 DNA Sequencing
  • 7.8.1 Overview
  • 7.8.2 DNA Sequencing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 7.9 Others
  • 7.9.1 Overview
  • 7.9.2 Others: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)

8. US Esoteric Testing Market - Revenue and Forecast to 2030 - by Type

• 8.1 Overview
• 8.2 US Esoteric Testing Market Revenue Share, by Type 2022 & 2030 (%)
• 8.3 Infectious Disease Testing
  • 8.3.1 Overview
  • 8.3.2 Infectious Disease Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Endocrinology Testing
  • 8.4.1 Overview
  • 8.4.2 Endocrinology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Oncology Testing
  • 8.5.1 Overview
  • 8.5.2 Oncology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.6 Toxicology Testing
  • 8.6.1 Overview
  • 8.6.2 Toxicology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.7 Immunology Testing
  • 8.7.1 Overview
  • 8.7.2 Immunology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.8 Neurology Testing
  • 8.8.1 Overview
  • 8.8.2 Neurology Testing: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 8.9 Others
  • 8.9.1 Overview
  • 8.9.2 Others: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)

9. US Esoteric Testing Market - Revenue and Forecast to 2030 - by End User

• 9.1 Overview
• 9.2 US Esoteric Testing Market Revenue Share, by End User 2022 & 2030 (%)
• 9.3 Hospitals & Laboratories
  • 9.3.1 Overview
  • 9.3.2 Hospitals & Laboratories: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 Independent & Reference Laboratories
  • 9.4.1 Overview
  • 9.4.2 Independent & Reference Laboratories: US Esoteric Testing Market - Revenue and Forecast to 2030 (US$ Million)

10. US Esoteric Testing Market -Industry Landscape

• 10.1 Overview
• 10.2 Organic Developments
  • 10.2.1 Overview
• 10.3 Inorganic Developments
  • 10.3.1 Overview

11. Company Profiles

• 11.1 Georgia Esoteric & Molecular Laboratory LLC
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Laboratory Corp of America Holdings
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Quest Diagnostics Inc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 National Medical Services Inc
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 OPKO Health Inc
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 ARUP Laboratories Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 bioMONTR Labs
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 Athena Esoterix LLC
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 Stanford Hospital & Clinics
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments
• 11.10 Foundation Medicine Inc
  • 11.10.1 Key Facts
  • 11.10.2 Business Description
  • 11.10.3 Products and Services
  • 11.10.4 Financial Overview
  • 11.10.5 SWOT Analysis
  • 11.10.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms